Holobeam Technologies is a Bethpage, New York biotech developing Holographic Energy Teleportation (HET), a patented method of focusing energy to precise microscopic locations inside the body. Paired with antibody-guided AdvaNan nanoparticles, the approach - branded the Holothermia protocol - aims to both detect individual cancer cells earlier than conventional imaging and heat them to death while sparing surrounding tissue. Founded by prolific inventor Gene Dolgoff, the LCD-projector pioneer who says he conceived the Star Trek Holodeck, the company is building HET-based MRI and portable scanners for diagnosis and treatment.

Akira Robinson is a biotech and pharmaceutical commercialization leader with roughly two decades of experience turning early-stage science into market-ready medicine. He is a Partner and Chief Experience Officer at the life-sciences consultancy Scimitar Inc. and serves as interim Chief Commercial Officer at Nucleus RadioPharma. He built and scaled the launch practice at EVERSANA to more than 20 consultants, and has stepped into interim CCO and COO seats across the industry. With a Harvard biochemistry degree, a Johns Hopkins biotech master's, and a stint as a Wall Street biotech equity analyst, he blends scientific fluency with commercial operating chops, lately focused on radiopharmaceutical therapies and AI-driven commercialization.
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies (TAT) for cancer, powered by its proprietary Lead-212 (212Pb) alpha isotope generator technology. By solving the chronic supply bottleneck of alpha-emitting isotopes, AdvanCell aims to deliver highly potent, tumor-specific radiation that destroys cancer cells while sparing healthy tissue. Its lead asset, ADVC001, a 212Pb-PSMA therapy, is in clinical trials for metastatic prostate cancer, with a deepening pipeline targeting melanoma, ovarian, breast, and lung cancers.
Ratio Therapeutics is a Boston-based clinical-stage biotech engineering next-generation targeted radiopharmaceuticals for solid tumors. Its proprietary Trillium and Macropa platforms tune how radioactive cancer-killing payloads travel through the body, aiming to deliver a lethal dose to tumors while sparing healthy tissue. Backed by major pharma partners including Novartis, Bayer, Lantheus and Bristol Myers Squibb, Ratio is advancing FAP- and SSTR2-targeted programs from imaging into therapy.
Bill Cupelo is the Chief Business Officer of Ratio Therapeutics, a Boston-based biotech building targeted radiopharmaceuticals that aim to both image and treat cancer. A chemist by training who learned to sell science, he spent more than a decade at imaging CRO Invicro, climbing from software product manager to head of sales, before bringing his sponsor-side, science-first mindset to Ratio's pipeline of alpha-emitting radioligand therapies. He also serves as Treasurer of the Massachusetts Nuclear Medicine & Radiopharmaceutical Council.